Compare PDLB & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | AQST |
|---|---|---|
| Founded | 1960 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.9M | 707.6M |
| IPO Year | 2017 | 2018 |
| Metric | PDLB | AQST |
|---|---|---|
| Price | $16.46 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | 63.4K | ★ 5.9M |
| Earning Date | 01-29-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.83 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $96,252,000.00 | $43,397,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $8.59 | $43.02 |
| P/E Ratio | $18.47 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $10.88 | $2.12 |
| 52 Week High | $18.01 | $7.55 |
| Indicator | PDLB | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 20.39 |
| Support Level | $15.84 | $3.21 |
| Resistance Level | $16.61 | $3.60 |
| Average True Range (ATR) | 0.48 | 0.34 |
| MACD | -0.04 | -0.31 |
| Stochastic Oscillator | 63.30 | 2.81 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.